Jefferies assumed coverage of GSK (GSK) with a Buy rating and 2,000 GBp price target At a 30% discount, GSK “offers significant upside skew” and all that is required is for the new CEO to buy some time via an efficiency program given that there are green shoots within the pipeline and room for business development, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK acquires exclusive rights from Syndivia for ADC in prostate cancer
- GSK Earnings this Week: How Will it Perform?
- Sell Rating for GlaxoSmithKline Due to Limited Growth Prospects for Blenrep Amid Competitive Challenges and Regulatory Hurdles
- Sell Rating Issued for GlaxoSmithKline’s Blenrep Due to Restrictive Approval and Market Limitations
- GSK’s Blenrep approved by FDA for treatment of relapsed multiple myeloma